Page 61 - Read Online

Le et al. J Transl Genet Genom 2018;2:17. I https://doi.org/10.20517/jtgg.2018.28 Page 7 of 9

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Dr. James J. Hsieh is a consultant for Eisai Inc.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, et al. Renal cell carcinoma. Nat Rev Dis Primers 2017;3:17009.
2. Hakimi AA, Pham CG, Hsieh JJ. A clear picture of renal cell carcinoma. Nat Genet 2013;45:849-50.
3. Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer
Cell 2016;29:104-16.
4. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature
2013;499:43-9.
5. Hsieh JJ, Le V, Cao D, Cheng E. Genomic classifications of renal cell carcinoma: a critical step towards the future personalized kidney
cancer care with pan-omics precision. J Pathol 2018;244:525-37.
6. Hsieh JJ, Manley BJ, Khan N, Gao J, Carlo MI, et al. Overcome tumor heterogeneity-imposed therapeutic barriers through convergent
genomic biomarker discovery: a braided cancer river model of kidney cancer. Semin Cell Dev Biol 2017;64:98-106.
7. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 2013;123:3664-71.
8. Masson N, Ratcliffe PJ. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological
pathways. Cancer Metab 2014;2:3.
9. Courtney KD, Infante JR, Lam ET, Choueiri TK. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α
antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J Clin Onc 2018;36:867-74.
10. Hakimi AA, Tickoo SK, Jacobsen A, Sarungbam J, Sfakianos JP, et al. TCEB1-mutated renal cell carcinoma: a distinct genomic and
morphological subtype. Mod Pathol 2015;28:845-53.
11. Kibel A, Iliopoulous O, DeCaprio JA, Kaelin WG Jr. Binding of the von Hippel-Lindau tumor suppressor protein to Elong B and C. Science
1995;269:1444-6.
12. Rohan SM, Xiao Y, Liang Y, Dudas ME, Al-Ahmadie HA, et al. Clear-cell papillary renal cell carcinoma: molecular and
immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway related proteins. Mod
Pathol 2011;24:1207-20.
13. Carroll VA, Ashcroft M. Role of hypoxia-induced factor (HIF)-1 alpha versus HIF-2 alpha in regulation of HIF target genes in response
to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the pathway. Cancer Res
2006;66:6264-70.
14. Shen C, Kaelin WG. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 2013;23:18-25.
15. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010;29:625-34.
16. Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ. Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal
cancers by expression of a constitutively active mutant of HIF1alpha. Cancer Res 2011;71:6848-56.
17. Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ. Activation of HIF2alpha in kidney proximal tubule cells causes abnormal glyogen
deposition but not tumorgenesis. Cancer Res 2013;73:2916-25.
18. Kondo K, Clco J, Nakamura E, Kaelin WG. Inhibition of HIF is necessary for tumor suppression by von Hippel-Lindau protein. Cancer
Cell 2002;1:237-46.
19. Zimmer M, Doucette D, Siddiqui N, Iliopoulous O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL -/-
tumors. Mol Cancer Res 2004;2:89-95.
20. Purdue MP, Johansson M, Zelenika D, Toro JR. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on
2p21 and 11q13.3. Nat Genet 2011;43:60-5.